{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T11:50:29Z","timestamp":1764417029374,"version":"3.46.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,29]]},"DOI":"10.7759\/cureus.98066","type":"journal-article","created":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T11:48:22Z","timestamp":1764416902000},"source":"Crossref","is-referenced-by-count":0,"title":["A Case of Multicentric Isocitrate Dehydrogenase-Wildtype Glioblastoma With Divergent Clonal Evolution"],"prefix":"10.7759","author":[{"given":"Nozomi","family":"Shibuya","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nayuta","family":"Higa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiaki","family":"Akahane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hajime","family":"Yonezawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mari","family":"Kirishima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihide","family":"Tanimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryosuke","family":"Hanaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-018-2831-7","article-title":"JCOG0911 INTEGRA study: a randomized screening phase II trial of interferon\u03b2 plus temozolomide in comparison with temozolomide alone for newly diagnosed glioblastoma","volume":"138","author":"Wakabayashi T","year":"2018","unstructured":"Wakabayashi T, Natsume A, Mizusawa J, et al.. JCOG0911 INTEGRA study: a randomized screening phase II trial of interferon\u03b2 plus temozolomide in comparison with temozolomide alone for newly diagnosed glioblastoma. J Neurooncol. 2018, 138:627-36. 10.1007\/s11060-018-2831-7","journal-title":"J Neurooncol"},{"key":"ref2","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(09)70025-7","article-title":"Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial","volume":"10","author":"Stupp R","year":"2009","unstructured":"Stupp R, Hegi ME, Mason WP, et al.. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009, 10:459-66.","journal-title":"Lancet Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-012-1030-1","article-title":"The incidence and significance of multiple lesions in glioblastoma","volume":"112","author":"Thomas RP","year":"2013","unstructured":"Thomas RP, Xu LW, Lober RM, Li G, Nagpal S. The incidence and significance of multiple lesions in glioblastoma. J Neurooncol. 2013, 112:91-7. 10.1007\/s11060-012-1030-1","journal-title":"J Neurooncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3171\/2012.7.JNS12147","article-title":"Prognosis of patients with multifocal glioblastoma: a case-control study","volume":"117","author":"Patil CG","year":"2012","unstructured":"Patil CG, Yi A, Elramsisy A, et al.. Prognosis of patients with multifocal glioblastoma: a case-control study. J Neurosurg. 2012, 117:705-11. 10.3171\/2012.7.JNS12147","journal-title":"J Neurosurg"},{"key":"ref5","doi-asserted-by":"crossref","DOI":"10.1016\/S0090-3019(98)00054-8","article-title":"Radiographic incidence of multicentric malignant gliomas","volume":"51","author":"Djalilian HR","year":"1999","unstructured":"Djalilian HR, Shah MV, Hall WA. Radiographic incidence of multicentric malignant gliomas. Surg Neurol. 1999, 51:554-8.","journal-title":"Surg Neurol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3171\/2010.6.JNS091326","article-title":"Multiple craniotomies in the management of multifocal and multicentric glioblastoma","volume":"114","author":"Hassaneen W","year":"2011","unstructured":"Hassaneen W, Levine NB, Suki D, et al.. Multiple craniotomies in the management of multifocal and multicentric glioblastoma. J Neurosurg. 2011, 114:576-84. 10.3171\/2010.6.JNS091326","journal-title":"J Neurosurg"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(194811)1:4<634::AID-CNCR2820010410>3.0.CO;2-L","article-title":"The use of the nitrogen mustards in the palliative treatment of carcinoma: with particular reference to bronchogenic carcinoma","volume":"1","author":"Karnofsky DA","year":"1948","unstructured":"Karnofsky DA, Abelmann WH, Craver LF, Burchenal JH. The use of the nitrogen mustards in the palliative treatment of carcinoma: with particular reference to bronchogenic carcinoma. Cancer. 1948, 1:634-56. 10.1002\/1097-0142(194811)1:4&lt;634::AID-CNCR2820010410&gt;3.0.CO;2-L","journal-title":"Cancer"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14597","article-title":"A tailored next-generation sequencing panel identified distinct subtypes of wildtype IDH and TERT promoter glioblastomas","volume":"111","author":"Higa N","year":"2020","unstructured":"Higa N, Akahane T, Yokoyama S, et al.. A tailored next-generation sequencing panel identified distinct subtypes of wildtype IDH and TERT promoter glioblastomas. Cancer Sci. 2020, 111:3902-11. 10.1111\/cas.14597","journal-title":"Cancer Sci"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1126\/science.1254257","article-title":"Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma","volume":"344","author":"Patel AP","year":"2014","unstructured":"Patel AP, Tirosh I, Trombetta JJ, et al.. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science. 2014, 344:1396-401. 10.1126\/science.1254257","journal-title":"Science"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/now231","article-title":"Comprehensive molecular characterization of multifocal glioblastoma proves its monoclonal origin and reveals novel insights into clonal evolution and heterogeneity of glioblastomas","volume":"19","author":"Abou-El-Ardat K","year":"2017","unstructured":"Abou-El-Ardat K, Seifert M, Becker K, et al.. Comprehensive molecular characterization of multifocal glioblastoma proves its monoclonal origin and reveals novel insights into clonal evolution and heterogeneity of glioblastomas. Neuro-Oncology. 2017, 19:546-57. 10.1093\/neuonc\/now231","journal-title":"Neuro-Oncology"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27372","article-title":"Telomerase reverse transcriptase promoter mutation is an early somatic genetic alteration in the transformation of premalignant nodules in hepatocellular carcinoma on cirrhosis","volume":"60","author":"Nault JC","year":"2014","unstructured":"Nault JC, Calderaro J, Di Tommaso L, et al.. Telomerase reverse transcriptase promoter mutation is an early somatic genetic alteration in the transformation of premalignant nodules in hepatocellular carcinoma on cirrhosis. Hepatology. 2014, 60:1983-92. 10.1002\/hep.27372","journal-title":"Hepatology"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1303607110","article-title":"TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal","volume":"110","author":"Killela PJ","year":"2013","unstructured":"Killela PJ, Reitman ZJ, Jiao Y, et al.. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A. 2013, 110:6021-6. 10.1073\/pnas.1303607110","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1093\/noajnl\/vdaa114","article-title":"TERT promoter mutation associated with multifocal phenotype and poor prognosis in patients with IDH wild-type glioblastoma","volume":"2","author":"Kikuchi Z","year":"2020","unstructured":"Kikuchi Z, Shibahara I, Yamaki T, et al.. TERT promoter mutation associated with multifocal phenotype and poor prognosis in patients with IDH wild-type glioblastoma. Neuro-oncol Adv. 2020, 2:vdaa114. 10.1093\/noajnl\/vdaa114","journal-title":"Neuro-oncol Adv"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1172\/JCI121303","article-title":"DNA hypermethylation within TERT promoter upregulates TERT expression in cancer","volume":"129","author":"Lee DD","year":"2019","unstructured":"Lee DD, Le\u00e3o R, Komosa M, et al.. DNA hypermethylation within TERT promoter upregulates TERT expression in cancer. J Clin Investig. 2019, 129:223-9. 10.1172\/JCI121303","journal-title":"J Clin Investig"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1093\/noajnl\/vdad110","article-title":"Alterations in EGFR and PDGFRA are associated with the localization of contrast-enhancing lesions in glioblastoma","volume":"5","author":"Makino R","year":"2023","unstructured":"Makino R, Higa N, Akahane T, et al.. Alterations in EGFR and PDGFRA are associated with the localization of contrast-enhancing lesions in glioblastoma. Neuro-oncol Adv. 2023, 5:vdad110. 10.1093\/noajnl\/vdad110","journal-title":"Neuro-oncol Adv"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2303815","article-title":"Dabrafenib plus trametinib in pediatric glioma with BRAF V600 mutations","volume":"389","author":"Bouffet E","year":"2023","unstructured":"Bouffet E, Hansford JR, Garr\u00e8 ML, et al.. Dabrafenib plus trametinib in pediatric glioma with BRAF V600 mutations. N Engl J Med. 2023, 389:1108-20. 10.1056\/NEJMoa2303815","journal-title":"N Engl J Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1111\/bpa.12217","article-title":"Pleomorphic xanthoastrocytoma: natural history and long-term follow-up","volume":"25","author":"Ida CM","year":"2015","unstructured":"Ida CM, Rodriguez FJ, Burger PC, et al.. Pleomorphic xanthoastrocytoma: natural history and long-term follow-up. Brain Pathol. 2015, 25:575-86. 10.1111\/bpa.12217","journal-title":"Brain Pathol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1007\/s10014-021-00407-0","article-title":"Predicting BRAF V600E mutation in glioblastoma: utility of radiographic features","volume":"38","author":"Natsumeda M","year":"2021","unstructured":"Natsumeda M, Chang M, Gabdulkhaev R, et al.. Predicting BRAF V600E mutation in glioblastoma: utility of radiographic features. Brain Tumor Pathol. 2021, 38:228-33. 10.1007\/s10014-021-00407-0","journal-title":"Brain Tumor Pathol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/437359-a-case-of-multicentric-isocitrate-dehydrogenase-wildtype-glioblastoma-with-divergent-clonal-evolution","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T11:48:23Z","timestamp":1764416903000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/437359-a-case-of-multicentric-isocitrate-dehydrogenase-wildtype-glioblastoma-with-divergent-clonal-evolution"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,29]]},"references-count":18,"URL":"https:\/\/doi.org\/10.7759\/cureus.98066","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11,29]]}}}